MERSANA THERAPEUTICS

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jan 2023 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Strategic Objectives and Expected Milestones

06 Jan 2023 06:00:18 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates

22 Dec 2022 15:05:10 By Nasdaq GlobeNewswire

European Commission Designates UpRi as an Orphan Medicinal Product for the Treatment of Ovarian Cancer

14 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Jefferies London Healthcare Conference

08 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

07 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022

31 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer

06 Oct 2022 15:05:37 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Launch of Oncology FACETS, a Resource for Healthcare Providers to Advance Knowledge in Gynecologic Malignancies

30 Sep 2022 07:02:05 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces FDA Fast Track Designation Granted to XMT-1660 for the Treatment of Triple-Negative Breast Cancer

12 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Present at Upcoming Investor Conferences

06 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-1660 in Breast, Endometrial and Ovarian Cancers

16 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

08 Aug 2022 15:04:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2

08 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire